Sporotrichosis, recognized by the World Health Organization (WHO) as a neglected tropical disease
and classified among significant fungal health concerns, remains both underestimated and underreported. There
is a profound impact of sporotrichosis on public health, affecting both humans and domestic animals. The causative
agents are fungi within the Sporothrix genus, primarily transmitted through traumatic exposure to contaminated
soil, plants, decomposing materials, or through scratches from infected animals, notably cats. While sporotrichosis
is a global concern, its prevalence is particularly noteworthy in tropical and subtropical regions. The
limited treatment options for sporotrichosis, with itraconazole as the preferred choice, underscore the challenges
posed by fungal infections. Issues such as toxicity and drug resistance further complicate effective management.
Consequently, this review aims to elucidate key objectives: identification of novel synthetic compounds revealed
in the literature, highlighting ongoing efforts to develop new treatments against sporotrichosis, examining
promising anti-sporothrix natural products, and providing an overview of endeavors to repurpose approved
drugs. The key findings from the study underscore the urgent need for diversified and effective drugs for the
treatment of Sporotrichosis.